▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1040 by analyst upside · 2026-06-27
ANTX
AN2 Therapeutics, Inc.
Healthcare · Market Cap $187M · P/E 0x
ANALYST PRICE TARGET
+73.1%
implied upside to consensus target
Current Price $5.2
Consensus Target $9.0
Bull Target $9.0
Bear Target $9.0
Analysts Covering 1
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
0
Hold
1
Sell
0
52-Week Low $1.0
52-Week High $6.91
YTD Return +368.5%
FUNDAMENTALS
Market Cap $187M
P/E Ratio (TTM) N/A
Forward P/E -5.0x
EPS (TTM) $-1.10
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.0
52-Week High $6.91
Current Price $5.2
Bear Target $9.0
Bull Target $9.0
● Now $5.2 ● Target $9.0
TRADING DATA
Avg Volume 283K
YTD Return +368.5%
Analyst Count 1
Consensus Hold
Upside to Target +73.1%
Last Updated 2026-06-27

ANALYST SUMMARY

AN2 Therapeutics, Inc. (ANTX) is currently trading at $5.2 with a Wall Street consensus price target of $9.0, implying potential upside of 73.1% over the next 12 months. 1 analysts currently cover ANTX, with a consensus rating of Hold - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $9.0, while the most cautious has a target of $9.0.

ANTX operates in the Healthcare sector with a market capitalisation of $187M. The stock is up 368.5% year-to-date and is currently trading near the upper end of its 52-week range of $1.0 – $6.91.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

WW +77.2%
WW International, Inc.
$160M · P/E 1.6x · Hold
INFU +48.0%
InfuSystem Holdings, Inc.
$203M · P/E 27.2x · Buy
SPRO +77.0%
Spero Therapeutics, Inc.
$131M · P/E 7.5x · Hold
ORMP +33.8%
Oramed Pharmaceuticals Inc.
$191M · P/E 1.8x · Hold
SPOK +31.5%
Spok Holdings, Inc.
$222M · P/E 18.1x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for ANTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ↑ Upgrade
Market Perform → Outperform 2026-05-14 29% win rate (7 calls)
JMP Securities — Reiterated
Market Outperform → Market Outperform 2025-05-05 Building track record
Citizens Capital Markets reit
Market Outperform → Market Outperform 2025-03-26 Building track record
Citizens Capital Markets reit
Market Outperform → Market Outperform 2025-02-25 Building track record
JMP Securities reit
Market Outperform → Market Outperform 2025-02-03 Building track record
JMP Securities reit
Market Outperform → Market Outperform 2024-11-19 Building track record
TD Cowen ↓ Downgrade
Buy → Hold 2024-11-18 Building track record
JMP Securities — Reiterated
Market Outperform → Market Outperform 2024-08-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
15
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →